Glioblastoma-initiating cell heterogeneity generated by the cell-of-origin, genetic/epigenetic mutation and microenvironment
Glioblastoma-initiating cell heterogeneity generated by the cell-of-origin, genetic/epigenetic mutation and microenvironment
复制标题
DOI：
10.1016/j.semcancer.2020.12.003
复制
发表时间：
2022-05-10
影响因子：
14.5
通讯作者：
Kondo, Toru
中科院分区：
文献类型：
--
作者：
Kondo, Toru
胶质母细胞瘤（GBM）和其他恶性肿瘤由异质性癌细胞组成，包括GBM起始细胞（GIC）。这种异质性可能源于以下方面：GIC在转化过程中获得的不同的基因突变和表观遗传修饰;起源细胞的差异，如干细胞，前体细胞或分化细胞;以及癌症微环境，其中GIC与神经细胞，内皮细胞和免疫细胞沟通。此外，考虑到各种类型的GIC可以在转化过程的不同时间点产生，GBM很可能由异质GIC及其后代组成。由于癌细胞的异质性是治疗抗性的原因，因此开发减少这种异质性的方法至关重要。在这里，我总结了GIC异质性是如何在转化过程中产生的，并介绍了如何根据最近的发现来解决癌症中的细胞异质性。
Glioblastoma (GBM) and other malignant tumours consist of heterogeneous cancer cells, including GBMinitiating cells (GICs). This heterogeneity is likely to arise from the following: different sets of genetic mutations and epigenetic modifications, which GICs gain in the transformation process; differences in cells of origin, such as stem cells, precursor cells or differentiated cells; and the cancer microenvironment, in which GICs communicate with neural cells, endothelial cells and immune cells. Furthermore, considering that various types of GICs can be generated at different time points of the transformation process, GBM very likely consists of heterogeneous GICs and their progeny. Because cancer cell heterogeneity is responsible for therapy resistance, it is crucial to develop methods of reducing such heterogeneity. Here, I summarize how GIC heterogeneity is generated in the transformation process and present how cell heterogeneity in cancer can be addressed based on recent findings.